ABSTRACT

PD-L1 ANTAGONIST COMBINATION TREATMENTS

The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

(No suitable figure)